Holen Sie sich die Stockscreener-App
3.01
1.33%
0.010
Schlusskurs vom Vortag:
$3.00
Offen:
$3.04
24-Stunden-Volumen:
125.40K
Relative Volume:
0.15
Marktkapitalisierung:
$98.87M
Einnahmen:
$1.23M
Nettoeinkommen (Verlust:
$-28.62M
KGV:
-1.9174
EPS:
-1.5698
Netto-Cashflow:
$-14.11M
1W Leistung:
+4.47%
1M Leistung:
+35.11%
6M Leistung:
+13.86%
1J Leistung:
+58.33%
1-Tages-Spanne:
$2.95
$3.09
1-Wochen-Bereich:
$2.88
$3.21
52-Wochen-Spanne:
$1.62
$3.84
Nrx Pharmaceuticals Inc Stock (NRXP) Company Profile
Firmenname
Nrx Pharmaceuticals Inc
Sektor
Branche
Telefon
484-254-6134
Adresse
1201 ORANGE STREET, WILMINGTON
Compare NRXP vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NRXP
Nrx Pharmaceuticals Inc
|
2.99 | 100.53M | 1.23M | -28.62M | -14.11M | -1.5698 |
VRTX
Vertex Pharmaceuticals Inc
|
428.12 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
705.22 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
800.76 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
305.58 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Nrx Pharmaceuticals Inc Stock (NRXP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-04-02 | Eingeleitet | BTIG Research | Buy |
Nrx Pharmaceuticals Inc Aktie (NRXP) Neueste Nachrichten
NRX Pharmaceuticals Is Maintained at Buy by D. Boral Capital - Moomoo
NRx Pharmaceuticals, Inc. (NRXP) Latest Stock News & Headlines - Yahoo Finance
Amid ketamine shortages, NRx begins making a preservative-free U.S. version - Stock Titan
NRx Pharmaceuticals (Nasdaq:NRXP) Announces Initiation of Commercial Manufacturing for Preservative Free Ketamine - Yahoo Finance
NRXP Stock Price, Quote & Chart | NRX PHARMACEUTICALS INC (NASDAQ:NRXP) - ChartMill
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Sees Large Growth in Short Interest - MarketBeat
NRx Pharmaceuticals, Inc. (NRXP) surpasses Q4 earnings estimates - MSN
NRx Reports FDA Feedback, Progress on Ketamine Application - MyChesCo
Equities Analysts Offer Predictions for NRXP Q1 Earnings - MarketBeat
Analysts Offer Insights on Healthcare Companies: Dogwood Therapeutics (DWTX), NRX Pharmaceuticals (NRXP) and Immuneering (IMRX) - The Globe and Mail
NRXP Forecast, Price Target & Analyst Ratings | NRX PHARMACEUTICALS INC (NASDAQ:NRXP) - ChartMill
NRx Pharmaceuticals (NASDAQ:NRXP) Earns "Buy" Rating from HC Wainwright - MarketBeat
NRx Pharmaceuticals (NASDAQ:NRXP) Price Target Raised to $49.00 at Ascendiant Capital Markets - MarketBeat
H.C. Wainwright reiterates NRx Pharmaceuticals stock rating on FDA progress - Investing.com
H.C. Wainwright reiterates NRx Pharmaceuticals stock rating on FDA progress By Investing.com - Investing.com India
NRx Pharmaceuticals gets FDA approval for suitability petition of Ketafree - MSN
New to The Street Broadcasts Show #746 Tonight on Bloomberg Television 6:30PM EST Featuring NRx Pharma (NASDAQ:NRXP), Performance Golf, Lost Soldier Oil & Gas, Dr. Lee Gause, and CISO Global - Scott Coop
Positive FDA Response on Preservative-Free Ketamine After President Trump Orders Accelerated Approval for Psychedelic Medication Developers Including NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) - Barchart.com
NRx Pharmaceuticals (NASDAQ: NRXP) Receives Positive FDA Review Letter Supporting Ketamine ANDA Progress - Barchart.com
NRx Pharmaceuticals receives FDA positive review for ketamine ANDA By Investing.com - Investing.com India
NRXP (NRX Pharmaceuticals Inc.) posts wider than expected Q4 2025 loss even as shares rise modestly today.Earnings Season - Cổng thông tin điện tử tỉnh Tây Ninh
NRX Pharmaceuticals (NRXP) Sector Rotation | Q4 2025: Earnings Fall ShortProfessional Trade Ideas - Xã Thanh Hà
NRX Pharmaceuticals, Inc. Common Stock (NRXP) Stock Price Today & Analysis - Gotrade
Positive FDA Response on Preservative-Free Ketamine After - openPR.com
NRx Pharmaceuticals receives FDA positive review for ketamine ANDA - Investing.com
NRx Pharmaceuticals Reports Positive FDA Office of Generic Drugs Feedback on Preservative-Free Ketamine Program - The Manila Times
NRXP Financials: Income Statement, Balance Sheet & Cash Flow | Nrx Pharmaceuticals Inc - Stock Titan
FinancialContentPresidential Executive Order to Accelerate Approval of Psychedelic Medications; Those Being Developed by NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) - FinancialContent
NRXP Ownership | NRX PHARMACEUTICALS INC (NASDAQ:NRXP) - ChartMill
NRx Pharmaceuticals Appoints Glenn Tyson as Chief Commercial Officer - MyChesCo
NRx Pharmaceuticals, Inc. (NRXPW) Stock Price, News, Quote & History - Yahoo Finance
NRx Re-Files FDA Application for Preservative-Free IV Ketamine - MSN
NRx Pharmaceuticals Welcomes Presidential Initiative to Accelerate Approval of Psychedelic Medications to Treat Depression, PTSD, and Suicidality - Investing News Network
NRx Pharmaceuticals (NASDAQ: NRXP) Supports Executive Order To Accelerate Psychedelic Drug Development - The Globe and Mail
NRx Pharmaceuticals welcomes the newly-signed Executive Order - TipRanks
NRx Pharmaceuticals' (NRXP) Buy Rating Reiterated at D. Boral Capital - MarketBeat
NRx Pharmaceuticals (Nasdaq:NRXP) Welcomes Presidential Initiative to Accelerate Approval of Psychedelic Medications to Treat Depression, PTSD, and Suicidality - ChartMill
NRx says FDA finds no bioequivalence issues in ketamine filing - MSN
NRx Pharmaceuticals Advances Robotic-Enabled Transcranial Magnetic Stimulation Combined with Neuroplastic Therapy for Military and First Responder Applications - Investing News Network
User - The Chronicle-Journal
NRx Pharmaceuticals forms defense R&D subsidiary By Investing.com - Investing.com Australia
AI-Driven Neurotechnology Expansion as FDA Path Clears and New Defense Initiative Emerges for NRx Pharmaceuticals (N A S D A Q: NRXP) - WFMZ.com
NRx Pharmaceuticals (NASDAQ: NRXP) Forms NRx Defense Systems Subsidiary to Advance Neuroplastic Therapies for Military and Government Applications - Barchart
Finanzdaten der Nrx Pharmaceuticals Inc-Aktie (NRXP)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.14%
2.09%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):